WO2003020222A3 - PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE - Google Patents

PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE Download PDF

Info

Publication number
WO2003020222A3
WO2003020222A3 PCT/US2002/028078 US0228078W WO03020222A3 WO 2003020222 A3 WO2003020222 A3 WO 2003020222A3 US 0228078 W US0228078 W US 0228078W WO 03020222 A3 WO03020222 A3 WO 03020222A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
dependent
dependent rna
inhibiting
rna viral
Prior art date
Application number
PCT/US2002/028078
Other languages
French (fr)
Other versions
WO2003020222A2 (en
Inventor
Steven S Carroll
Malcolm Maccoss
Lawrence C Kuo
David B Olsen
Balkrishen Bhat
Anne Bettina Eldrup
Marija Prhavc
Leila Malik
Sanjib Bera
Original Assignee
Merck & Co Inc
Isis Pharmaceuticals Inc
Steven S Carroll
Malcolm Maccoss
Lawrence C Kuo
David B Olsen
Balkrishen Bhat
Anne Bettina Eldrup
Marija Prhavc
Leila Malik
Sanjib Bera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Isis Pharmaceuticals Inc, Steven S Carroll, Malcolm Maccoss, Lawrence C Kuo, David B Olsen, Balkrishen Bhat, Anne Bettina Eldrup, Marija Prhavc, Leila Malik, Sanjib Bera filed Critical Merck & Co Inc
Priority to AU2002329970A priority Critical patent/AU2002329970A1/en
Publication of WO2003020222A2 publication Critical patent/WO2003020222A2/en
Publication of WO2003020222A3 publication Critical patent/WO2003020222A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

The present invention provides 1,3-dioxolane and 1,3-oxathiolane derivatives that are inhibitors of RNA-dependent RNA viral polymerase. These compounds are also inhibitors of RNA-dependent RNA viral replication and are useful in the treatment of RNA-dependent RNA viral infection. The invention also describes pharmaceutical compositions containing such 1,3-dioxolane and 1,3-oxathiolane derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection. Also disclosed are methods of inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the compounds of the present invention.
PCT/US2002/028078 2001-09-04 2002-08-29 PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE WO2003020222A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002329970A AU2002329970A1 (en) 2001-09-04 2002-08-29 Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31707001P 2001-09-04 2001-09-04
US60/317,070 2001-09-04

Publications (2)

Publication Number Publication Date
WO2003020222A2 WO2003020222A2 (en) 2003-03-13
WO2003020222A3 true WO2003020222A3 (en) 2003-11-27

Family

ID=23231976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/028078 WO2003020222A2 (en) 2001-09-04 2002-08-29 PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE

Country Status (2)

Country Link
AU (1) AU2002329970A1 (en)
WO (1) WO2003020222A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549079A (en) 2004-02-20 2010-08-27 Boehringer Ingelheim Int Viral polymerase inhibitors
WO2016180691A1 (en) 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
US9708359B2 (en) 2015-08-06 2017-07-18 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
CA3087354C (en) * 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5922867A (en) * 1995-12-14 1999-07-13 Biochem Pharma Inc. Method and compositions for the synthesis of dioxolane nucleosides with β configuration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5922867A (en) * 1995-12-14 1999-07-13 Biochem Pharma Inc. Method and compositions for the synthesis of dioxolane nucleosides with β configuration

Also Published As

Publication number Publication date
WO2003020222A2 (en) 2003-03-13
AU2002329970A1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
WO2002057425A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004009020A3 (en) Pyrrolopyrimidine thionucleoside analogs as antivirals
WO2006065335A3 (en) Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
AU2003240488A1 (en) Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
WO2003105770A3 (en) Carbocyclic nucleoside analogs as rna-antivirals
WO2007021610A3 (en) Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
NO20010743L (en) Antiviral indoloxoacetyl-piperazine derivatives
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2004026229A3 (en) Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
WO2002088124A3 (en) Pyrazolo'1,5-a!pyridine derivatives
WO2005077954A3 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2002036734A3 (en) Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
WO2005048948A3 (en) Urea derivatives as kinase modulators
AU3595500A (en) Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
TW200612898A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
WO2003087088A3 (en) (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
WO2006034001A3 (en) Methods of treating hiv infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP